Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?

Author(s): Jacqueline P. Williams, Carl J. Johnston, Jacob N. Finkelstein.


Due to the radiosensitivity of the lung, toxic endpoints, in the form of radiation pneumonitis and pulmonary fibrosis, are relatively frequent outcomes following radiation treatment of thoracic neoplasms. Because of the potential lethal nature of these normal tissue reactions, they not only lead to quality-of-life issues in survivors, but also are deemed dose-limiting and thereby compromise treatment. The mitigation and treatment of lung normal tissue late effects has therefore been the goal of many investigations; however, the complexity of both the organ itself and its response to injury has resulted in little success. Nonetheless, current technology allows us to propose likely targets that are either currently being researched or should be considered in future studies.

Keywords: Radiation, lung, pneumonitis, pulmonary fibrosis, pulmonary, neoplasms, bronchiole, endothelium, fibroblasts, FDA, (ROS), (SOD), Mn-SOD, (L-NAME), (iNOS), DNA damage, (SP-A), (COX-2), HMG-CoA, (MCP-1), Cytokine, (TNF), IL-1, TGF-ß, RAS, ACE

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2010
Page: [1386 - 1394]
Pages: 9
DOI: 10.2174/1389450111009011386
Price: $58